Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05595460 · ClinicalTrials.gov registry record · Phase 1
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
A Phase 1 study of SCLC,Extensive Stage, sponsored by RayzeBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 15
- Study locations
NCT05595460 is a Phase 1 study of SCLC,Extensive Stage that is actively recruiting participants, run by RayzeBio. The registered enrollment target is 49 participants. The trial reports 15 study locations across 11 states.
The verdict
NCT05595460, a Phase 1 study of SCLC,Extensive Stage, is actively recruiting participants, sponsored by RayzeBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG RYZ101 Dose Level 1
- DRUG RYZ101 Dose Level 2
- DRUG RYZ101 Dose Level 3
- DRUG RYZ101 Dose Level -1
Study Locations (15)
Florida
- Research Facility - Jacksonville
- Research Facility - Miami
- Research Facility - Orlando
California
- Research Facility - Los Angeles
- Research Facility - San Francisco
Michigan
- Research Facility - Grand Rapids
- Research Facility - Troy
Iowa
- Research Facility - Iowa City
Kentucky
- Reserach Facility - Lexington
Minnesota
- Research Facility - Rochester
Missouri
- Research Facility - St Louis
Nebraska
- Research Facility - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05595460
The ClinicalTrials.gov registry entry for NCT05595460 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RayzeBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SCLC,Extensive Stage appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT05595460 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05595460 about?
NCT05595460 is a clinical study titled "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC". This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
What is the current status of trial NCT05595460?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-10-10. Estimated completion is 2029-03.
What conditions does trial NCT05595460 study?
This clinical trial studies the following conditions: SCLC,Extensive Stage.
What interventions are being tested in trial NCT05595460?
The interventions under investigation include: Atezolizumab (DRUG), RYZ101 Dose Level 1 (DRUG), RYZ101 Dose Level 2 (DRUG), RYZ101 Dose Level 3 (DRUG), RYZ101 Dose Level -1 (DRUG).
Who is sponsoring clinical trial NCT05595460?
This trial is sponsored by RayzeBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05595460 being conducted?
This trial has 15 study locations across California, Florida, Iowa, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.